<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        49-82-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROTATEQ ORAL VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        G1 REASSORTANT,G2 REASSORTANT,G3 REASSORTANT,G4 REASSORTANT,PIA 8 REASSORTANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        nlt2.2*106,nlt2.8*106,nlt2.2*106,nlt2.0*106,nlt2.3*106
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        210.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP AND DOHME LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>RotaTeq is an oral vaccine that helps protect infants and young children against gastroenteritis (diarrhoea and vomiting) caused by rotavirus infection and may be given to infants from the age of 6 weeks to 32 weeks (see section 3). The vaccine contains five types of live rotavirus strains. When an infant is given the vaccine, the immune system (the body&rsquo;s natural defenses) will make antibodies against the most commonly occurring types of rotavirus. These antibodies help protect against gastroenteritis caused by these types of rotavirus.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child is allergic to any of the components of this vaccine (see section 6 Contents of the pack and other information).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child developed an allergic reaction after receiving a dose of RotaTeq or other rotavirus vaccine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child has previously had intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child was born with a malformation of the gastrointestinal system that might predispose for intussusception.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child has any disease which reduces his/her resistance to infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child has a severe infection with a high temperature. It might be necessary to postpone the vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to your doctor first.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child has diarrhoea or is vomiting. It might be necessary to postpone the vaccination until recovery.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before using RotaTeq if your child:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has received a blood transfusion or immunoglobulins within the last 6 weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has any disorder of the gastrointestinal system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has not been gaining weight and growing as expected.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or the mother has taken any medicine during pregnancy that weakens the immune system.</p><p>&nbsp;</p><p>After your child has received RotaTeq, contact a doctor/health care professional right away if your child experiences severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever (see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p>As always, please take care to wash your hands thoroughly after changing soiled nappies.</p><p>&nbsp;</p><p>As with other vaccines, RotaTeq may not completely protect all children who are vaccinated even after all three doses have been given.</p><p>&nbsp;</p><p>If your child has already been infected with rotavirus but is not yet ill when vaccinated, RotaTeq may not be able to prevent the illness.</p><p>&nbsp;</p><p>RotaTeq does not protect against diarrhoea and vomiting due to causes other than rotavirus.</p><p>&nbsp;</p><p>Other medicines and RotaTeq</p><p><strong>&nbsp;</strong></p><p>RotaTeq may be given at the same time as your child receives other normally recommended vaccinations, such as diphtheria, tetanus, pertussis (whooping cough), <em>Haemophilu</em>s <em>influenzae </em>type b, inactivated or oral poliomyelitis, hepatitis B, pneumococcal conjugate and meningococcus group C conjugate vaccines.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines (or other vaccines).</p><p>&nbsp;</p><p>RotaTeq with food and drink</p><p><strong>&nbsp;</strong></p><p>There are no restrictions on taking food or liquid, including breast milk, either before or after vaccination with RotaTeq.</p><p>&nbsp;</p><p>RotaTeq contains sucrose</p><p><strong>&nbsp;</strong></p><p>If you have been told that your child has an intolerance to some sugars, inform your doctor/health care professional before the vaccine is administered.</p><p>&nbsp;</p><p>RotaTeq contains sodium</p><p><strong>&nbsp;</strong></p><p>This vaccine contains 37.6 mg sodium (main component of cooking/table salt) in each dose. This is equivalent to 1.88% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>RotaTeq IS FOR ORAL USE ONLY.</strong></p><p><strong>&nbsp;</strong></p><p>A doctor or nurse will administer the recommended doses of RotaTeq to your child. The vaccine will be given by gently squeezing the tube and delivering the vaccine into your child&rsquo;s mouth.</p><p>The vaccine can be given without regard to food, liquid, or breast milk.</p><p>In case your child spits out or regurgitates most of the vaccine dose, a single replacement dose may be given at the same vaccination visit.</p><p>&nbsp;</p><p>Under no circumstance should this vaccine be administered by injection.</p><p>&nbsp;</p><p>The first dose (2 ml) of RotaTeq may be given from the age of 6 weeks and should be given before</p><p>12 weeks of age (about 3 months). RotaTeq may be given to infants who were born early provided that the pregnancy had lasted at least 25 weeks. These infants should receive the first dose of vaccine between 6 and 12 weeks after birth.</p><p>&nbsp;</p><p>Your child will receive 3 doses of RotaTeq given at least four weeks apart. It is important that your child receives all 3 doses of the vaccine for protection against rotavirus. It is preferred that all three doses should be given by the age of 20-22 weeks and at latest all three doses should be given by the age of 32 weeks.</p><p>&nbsp;</p><p>When RotaTeq is given to your child for the first dose, it is recommended that your child also receives RotaTeq (and not another rotavirus vaccine) to complete the vaccination course.</p><p>&nbsp;</p><p>If you forget an appointment for RotaTeq</p><p><strong>&nbsp;</strong></p><p>It is important that you follow the instructions of your doctor/health care professional regarding your child&rsquo;s return visits for the follow-up doses. If you forget or are not able to go back to your doctor/health care professional at the scheduled time, ask him or her for advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact a doctor/health care professional right away if your child experiences one of the following symptoms:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (frequency cannot be estimated from the available data), which may be severe (anaphylaxis), and may include: allergic swelling that may affect the face, lips, tongue or throat.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchospasm (rare, may affect up to 1 in 1000 infants). This may present as wheezing, coughing or difficulty breathing.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever. These could be symptoms of a very rare (may affect up to 1 in 10,000 infants), but serious, side effect called intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment).</p><p>&nbsp;</p><p>&nbsp;</p><p>The following other side effects reported with the use of RotaTeq were:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Very common (may affect more than 1 in 10 infants): fever, diarrhoea, vomiting</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 in 10 infants): infections of the upper respiratory system</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 infants): stomach pains (see also above for signs of a very rare side effect of intussusception), runny nose and sore throat, ear infection, rash, blood in stool</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Rare (may affect up to 1 in 1000 infants): hives</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Not known (frequency cannot be estimated from the available data): irritability</p><p>&nbsp;</p><p>In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.</p><p>&nbsp;</p><p>Ask your doctor/health care professional if you want more information about side effects for RotaTeq.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC), SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this vaccine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this vaccine after the expiry date which is stated on the label after EXP. &nbsp;The expiry date is written on both outer carton &amp; inner inner label.</p><p>&nbsp;</p><p>Store and transport refrigerated (2 &deg;C to 8 &deg;C). Keep the dosing tube in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances in RotaTeq are 5 human-bovine reassortant rotavirus strains: G1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2 x 10<sup>6</sup> Infectious Units</p><p>G2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.8 x 10<sup>6</sup> Infectious Units</p><p>G3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2 x 10<sup>6</sup> Infectious Units</p><p>G4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.0 x 10<sup>6</sup> Infectious Units</p><p>P1A[8]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.3 x 10<sup>6</sup> Infectious Units</p><p>&nbsp;</p><p>The other ingredients in RotaTeq are: sucrose, sodium citrate, sodium dihydrogen phosphate monohydrate, sodium hydroxide, polysorbate 80, culture media (containing inorganic salts, amino acids and vitamins), and purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oral solution

This vaccine is contained in a single-dose tube and is a pale yellow clear liquid that may have a pink tint.
RotaTeq is available in pack size of 1, 10 dosing tubes. Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck Sharp &amp; Dohme B.V.,</p><p>Waarderweg 39 ,2031 BN Haarlem,</p><p>P.O.Box 581, 2003 Haarlem,</p><p>The Netherlands</p><p><strong>Manufacturer: </strong></p><p>Merck, Sharp &amp; Dohme LLC, 770 Sumneytown Pike, P.O. Box<br />4, West Point, PA 19486, US.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2023

•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC), at SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
-	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to Instructions are dangerous for you.
-	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
-	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-	Do not by yourself interrupt the period of treatment prescribed for you.
-	Do not repeat the same prescription without consulting your doctor.
-	Keep all medicaments out of reach of children.
Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">روتاتك هو لُقاح يُعطى عن طريق الفم يساعد على حماية الرضع والأطفال الصغار ضد التهاب المعدة والأمعاء (الإسهال والقيء) الناجم عن عدوى فيروس الروتا، ويمكن إعطاؤه للرضع بدءًا من عمر 6 أسابيع إلى 32 أسبوعا (انظر الفقرة رقم 3). يحتوي اللقاح على خمسة أنواع من سلالات فيروس الروتا الحيّة. عندما يُعطى الرضيع اللقاح، يبدأ الجهاز المناعي (الدفاعات الطبيعية للجسم) لديه بتكوين الأجسام المضادة ضد الأنواع الأكثر شيوعا من فيروس الروتا. هذه الأجسام المضادة تساعد على الحماية ضد التهاب المعدة والأمعاء الناجم عن هذه الأنواع من فيروس الروتا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم روتاتك إذا:</strong></p><p dir="RTL">- &nbsp;كان لدى طفلك حساسية نحو أي من مكونات هذا اللقاح (انظر الفقرة رقم 6 محتويات العبوة ومعلومات<br />&nbsp;&nbsp; أخرى).<br />- &nbsp;تعرَض طفلك في السابق لرد فعل تحسسي بعد تلقيه لجرعة من روتاتك أو أي لقاح آخر مضاد لفيروس<br />&nbsp;&nbsp;&nbsp; الروتا.<br />- &nbsp;تعرّض طفلك في السابق للانغلاف المعوي (انزلاق جزء من الأمعاء داخل جزء آخر مما يؤدي لانسداد<br />&nbsp;&nbsp;&nbsp; الأمعاء(.<br />- &nbsp;كان لدى طفلك تشوه خَلقي في الجهاز الهضمي يمكن أن يُعرضه للإنغلاف المعوي.<br />- &nbsp;كان &nbsp;طفلك يعاني من أي مرض يقلل من مقاومته/مقاومتها للعدوى.<br />- &nbsp;كان طفلك يعاني من عدوى شديدة مع ارتفاع في درجة الحرارة. قد يكون من الضروري تأجيل التطعيم<br />&nbsp;&nbsp; حتى يتعافى. ولا ينبغي أن تكون هناك مشكلة مع العدوى الخفيفة مثل الرّشح، ولكن استشر طبيبك أولا.<br />- &nbsp;كان طفلك يعاني من الإسهال أو التقيؤ، قد يكون من الضروري تأجيل التطعيم حتى يتعافى.</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل استخدام روتاتك إذا كان طفلك:</p><p dir="RTL">- &nbsp;قد تلقى نقل الدم أو الجلوبولين المناعي خلال الأسابيع الستة الماضية.<br />- &nbsp;على اتصال مباشر مع شخص مثل أحد أفراد الأسرة لديه ضعف في الجهاز المناعي، على سبيل المثال، شخص مصاب بالسرطان أو يتناول أدوية قد تضعف جهاز المناعة.<br />-&nbsp; &nbsp;لديه أي اضطراب في الجهاز الهضمي.<br />- &nbsp;&nbsp;لم يزداد وزنه ونموه كما هو متوقع.</p><p dir="RTL">- &nbsp;&nbsp;أو أن الأم قد تناولت أي دواء أثناء الحمل الذي قد يضعف الجهاز المناعي.</p><p dir="RTL">بعد تلقي طفلك روتاتك، ينبغي عليك الاتصال بالطبيب / أخصائي الرعاية الصحية على الفور إذا تعرّض &nbsp;طفلك لآلام شديدة في المعدة، والتقيؤ المستمر، والدم في البراز، وتورم البطن و / أو ارتفاع في درجة الحرارة (انظر أيضا الفقرة رقم 4 &quot;الآثار الجانبية المحتملة&quot;) .</p><p dir="RTL">كما هو الحال دائما، يرجى الحرص على غسل يديك جيدا بعد تغيير الحفاضات المتسخة.</p><p dir="RTL">وكما هو الحال مع اللقاحات الأخرى، قد لا يُؤمّن روتاتك الحماية الكاملة لجميع الأطفال الذين يتلقّون اللقاح &nbsp;حتى بعد إعطاء جميع الجرعات الثلاث.</p><p dir="RTL">إذا تلقى طفلك اللقاح وهو مصاب بالفعل بفيروس الروتا ولكن قبل أن تظهر عليه أعراض المرض، قد لا يتمكن لقاح روتاتك من منع ظهور المرض.</p><p dir="RTL">روتاتك لا يحمي ضد الإسهال والقيء الناجم عن أسباب أخرى غير فيروس الروتا.</p><p dir="RTL"><strong>أدوية أخرى و روتاتك:</strong></p><p dir="RTL">يمكن إعطاء لقاح روتاتك لطفلك مع لقاحات الأطفال الروتينيّة في نفس الوقت، مثل الدفتيريا والكزاز والشاهوق &quot;السعال الديكي&quot; والمستدمية النزلية من النوع ب (هيموفيلاس انفلونزا ب)، وشلل الأطفال الذي يُعطى عن طريق الفم أو الحيّ المُضعّف، والتهاب الكبد B، والمكورات الرئوية المُقترنة والمكورات السحائية &nbsp;المقترنة مجموعة c.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كان طفلك يستخدم، قد استخدم مؤخّرًا أو قد يستخدم أيّ أدوية أخرى (أو لقاحات أخرى).</p><p dir="RTL"><strong>روتاتك مع الطعام والشراب</strong></p><p dir="RTL">لا توجد قيود على تناول الطعام أو الشراب، بما في ذلك حليب الثدي، إما قبل أو بعد التطعيم بروتاتك.</p><p dir="RTL"><strong>روتاتك يحتوي على السكروز</strong></p><p dir="RTL">إذا سبق لك العلم أنّ طفلك يعاني من عدم تحمل لبعض السكريات، فأبلغ طبيبك / أخصائي الرعاية الصحية قبل إعطاء اللقاح.</p><p>Arabic translation.&nbsp;</p><p dir="RTL"><strong>روتاتك يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا اللقاح على 37,6 &nbsp;ملغ صوديوم(المكون الرئيسي للطهي/ ملح الطعام) في كل جرعة . وهذا يعادل 1,88% من الحد الأقصى الموصى به من الجرعة الغذائية اليومية للصوديوم للبالغين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>روتاتك مُعد للاستخدام عن طريق الفم فقط.</strong></p><p dir="RTL">سيقوم الطبيب أو الممرضة بإعطاء الجرعات الموصى بها من روتاتك لطفلك. سيتم إعطاء اللقاح عن طريق الضغط بلطف على أنبوب اللقاح و سكب الجرعة في فمه .</p><p dir="RTL">يمكن إعطاء اللقاح بغض النظر عن وقت تناول الطعام أو الشراب أو حليب الثدي.</p><p dir="RTL">في حالة بصَق طفلك أو تقيّأ معظم جرعة اللقاح، يمكن إعطاؤه جرعة واحدة بديلة في نفس الوقت.</p><p dir="RTL">يجب عدم إعطاء هذا اللقاح عن طريق الحقن تحت أي ظرف من الظروف.</p><p dir="RTL">يمكن إعطاء الجرعة الأولى (2 ملل) من روتاتك بدءًا من عمر 6 أسابيع على أن تُعطى قبل بلوغ الطفل 12 أسبوعا من العمر (حوالي 3 أشهر). ويمكن إعطاء روتاتك للرّضع الخِداج (ولدوا مبكرًا) بشرط أن يكون الحمل قد استمر 25 أسبوعا على الأقل. وينبغي أن يتلقى هؤلاء الرّضع الجرعة الأولى من اللقاح بين 6 و 12 أسبوعا بعد الولادة.</p><p dir="RTL">سيتلقّى طفلك 3 جرعات من روتاتك على أن تفصل بين كل جرعة وأخرى مدة زمنيّة لا تقل عن أربعة أسابیع. من المهم أن يتلقى طفلك كل الجرعات الثلاث من اللقاح للحماية من فيروس الروتا. ويفضل أن تُعطى جميع الجرعات الثلاث في سن 20-22 أسبوعا، وينبغي أن تعطى في نهاية المطاف جميع الجرعات الثلاث بحلول سن 32 أسبوعا.</p><p dir="RTL">عندما يتم إعطاء الجرعة الأولى من روتاتك لطفلك ، فمن المستحسن أن تُستكمل دورة التطعيم لطفلك (الجرعات الثلاث) باستخدام روتاتك أيضًا (وليس لقاح آخر من لقاحات فيروس الروتا). &nbsp;</p><p dir="RTL"><strong>إذا نسيت أحد مواعيد التطعيم بلقاح روتاتك:</strong></p><p dir="RTL">من المهم أن تتبع تعليمات الطبيب / أخصائي الرعاية الصحية بشأن مواعيد جرعات المتابعة. إذا نسيت أو لم تكن قادرا على زيارة طبيبك / أخصائي الرعاية الصحية في الوقت المحدد للجرعة، استشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>روتاتك مُعد للاستخدام عن طريق الفم فقط.</strong></p><p dir="RTL">سيقوم الطبيب أو الممرضة بإعطاء الجرعات الموصى بها من روتاتك لطفلك. سيتم إعطاء اللقاح عن طريق الضغط بلطف على أنبوب اللقاح و سكب الجرعة في فمه .</p><p dir="RTL">يمكن إعطاء اللقاح بغض النظر عن وقت تناول الطعام أو الشراب أو حليب الثدي.</p><p dir="RTL">في حالة بصَق طفلك أو تقيّأ معظم جرعة اللقاح، يمكن إعطاؤه جرعة واحدة بديلة في نفس الوقت.</p><p dir="RTL">يجب عدم إعطاء هذا اللقاح عن طريق الحقن تحت أي ظرف من الظروف.</p><p dir="RTL">يمكن إعطاء الجرعة الأولى (2 ملل) من روتاتك بدءًا من عمر 6 أسابيع على أن تُعطى قبل بلوغ الطفل 12 أسبوعا من العمر (حوالي 3 أشهر). ويمكن إعطاء روتاتك للرّضع الخِداج (ولدوا مبكرًا) بشرط أن يكون الحمل قد استمر 25 أسبوعا على الأقل. وينبغي أن يتلقى هؤلاء الرّضع الجرعة الأولى من اللقاح بين 6 و 12 أسبوعا بعد الولادة.</p><p dir="RTL">سيتلقّى طفلك 3 جرعات من روتاتك على أن تفصل بين كل جرعة وأخرى مدة زمنيّة لا تقل عن أربعة أسابیع. من المهم أن يتلقى طفلك كل الجرعات الثلاث من اللقاح للحماية من فيروس الروتا. ويفضل أن تُعطى جميع الجرعات الثلاث في سن 20-22 أسبوعا، وينبغي أن تعطى في نهاية المطاف جميع الجرعات الثلاث بحلول سن 32 أسبوعا.</p><p dir="RTL">عندما يتم إعطاء الجرعة الأولى من روتاتك لطفلك ، فمن المستحسن أن تُستكمل دورة التطعيم لطفلك (الجرعات الثلاث) باستخدام روتاتك أيضًا (وليس لقاح آخر من لقاحات فيروس الروتا). &nbsp;</p><p dir="RTL"><strong>إذا نسيت أحد مواعيد التطعيم بلقاح روتاتك:</strong></p><p dir="RTL">من المهم أن تتبع تعليمات الطبيب / أخصائي الرعاية الصحية بشأن مواعيد جرعات المتابعة. إذا نسيت أو لم تكن قادرا على زيارة طبيبك / أخصائي الرعاية الصحية في الوقت المحدد للجرعة، استشر طبيبك.</p><p dir="RTL"><strong>4. الآثار الجانبية المحتملة</strong></p><p dir="RTL">على غرار جميع اللقاحات والأدوية، يمكن أن يسبب هذا اللقاح آثارا جانبية، على الرغم من أنها لا تحدث لدى جميع من يتلقّاه.</p><p dir="RTL">اتصل بالطبيب / أخصائي الرعاية الصحية على الفور إذا تعرّض طفلك لأحد الأعراض التالية:</p><p dir="RTL">&bull; الحساسية (لا يمكن تقدير تكرار حدوثها من البيانات المتاحة)، والتي قد تكون شديدة (رد الحساسية المفرطة)، وقد تشمل: تورم تحسسي قد يُؤثر على الوجه والشفتين واللسان أو الحلق.</p><p dir="RTL">&bull; تشنج قصبي (نادر، قد يؤثر على ما يصل إلى 1 من بين 1000 طفل رضيع). قد يظهر على شكل &nbsp;صفير، وسعال أو صعوبة في التنفس.</p><p dir="RTL">&bull; ألم شديد في المعدة، تقيؤ مستمر، دم في البراز، انتفاخ في البطن و / أو ارتفاع في درجة الحرارة.<br />يمكن أن تكون هذه أعراض لتأثير جانبي نادر جدا (قد يؤثر على ما يصل إلى 1 من بين 10000 طفل رضيع)، لكنه خطير يسمى الانغلاف المعوي (انسداد الأمعاء الذي يحدث بسبب انزلاق جزء من الأمعاء داخل جزء آخر).</p><p dir="RTL">كما تم الإبلاغ أيضًا عن الآثار الجانبية الأخرى التالية مع استخدام روتاتك:</p><p dir="RTL">&bull; شائعة جدا (قد يؤثر على أكثر من 1 من بين 10 طفل): الحمى والإسهال والقيء</p><p dir="RTL">&bull; شائعة (قد تؤثر على ما يصل إلى 1 من بين 10 طفل): التهابات الجهاز التنفسي العلوي</p><p dir="RTL">&bull; غير شائعة (قد تؤثر على ما يصل إلى 1 من بين 100 طفل): آلام في المعدة (انظر أيضا أعلاه لعلامات أثر جانبي نادر جدا وهو الانغلاف المعوي)، سيلان الأنف والتهاب الحلق، عدوى الأذن، الطفح الجلدي، الدم في البراز</p><p dir="RTL">&bull; نادرة (قد تؤثر على ما يصل إلى 1 من 1000 طفل): الشرى</p><p dir="RTL">&bull; غير معروف (لا يمكن تقدير تكرار حدوثها من البيانات المتاحة): الهيجان</p><p dir="RTL">قد يتعرض الأطفال الخِداج (الذين ولدوا في الأسبوع 28 من الحمل أو قبله) إلى فترات أطول من المعتاد بين الأنفاس لمدة 2-3 أيام بعد التطعيم.</p><p dir="RTL">اسأل طبيبك / أخصائي الرعاية الصحية إذا كنت تريد المزيد من المعلومات حول الآثار الجانبية لروتاتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرّض طفلك لأي آثار جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية أخرى غير مُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة عن طريق المركز الوطني للتيقظ والسلامة الدوائية التابع لهيئة الغذاء والدواء السعودية. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا اللقاح بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصلاحية المُدرج على الملصق بعد EXP. تاريخ انتهاء الصلاحية مُدرج على كل من الكرتون الخارجي والمُلصق الداخلي.</p><p dir="RTL">يُحفظ و يُنقل في الثلاجة (2 - 8 درجة مئوية). احتفظ بأنبوب اللقاح داخل الكرتون الخارجي من أجل حمايته من الضوء.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة في روتاتك هي 5 سلالات من فيروس الروتا البشري &ndash; البقري المتفارز<br />G1: 2.2 &times; <sup>6</sup>10 وحدات معدية<br />G2: 2.8 &times; <sup>6</sup>10 وحدات معدية<br />G3: 2.2 &times; <sup>6</sup>10 وحدات معدية<br />G4: 2.0 &times; <sup>6</sup>10 وحدات معدية<br />P1A [8]: 2.3 &times; <sup>6</sup>10 وحدات معدية</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى في روتاتك هي:</p><p dir="RTL">سكروز (1080 ملغم)، سترات الصوديوم ثنائي الهيدرات (127 ملغم)، فوسفات الصوديوم دايهايدروجين مونوهايدريت (29.8 ملغم)، هيدروكسيد الصوديوم (2.75 ملغم)، بوليسوربات 80 (0.17 - 0.86 ملغم)، محلول مُخفف لفيروس الروتا و LPKM-3 (15٪ حجم/حجم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول يُعطى عن طريق الفم .</p><p dir="RTL">اللقاح مُعبّأ في أنبوب يحتوي على جرعة واحدة وهو سائل أصفر شاحب صافي قد يميل إلى اللون الوردي.</p><p dir="RTL">روتاييك متوفر في علب تحتوي 1 أو 10 أنابيب. قد لا يتم تسويق جميع أحجام العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حقوق التسويق:</strong></p><p dir="RTL">ميرك شارب و دوهم بي في<br />وارديرويج 39، 2031 بي إن هارلم،</p><p dir="RTL">ص.ب 581، 2003 هارلم،<br />هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المُصنعة :</strong></p><p dir="RTL">شركة ميرك شارب و دوهم ذ م م&nbsp;<br />770 سومنيتاون بايك<br />ويست بوينت، بنسلفانبا 19486، الولايات المتحدة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة مؤخرا في مارس 2023

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.

(إن هذا الدواء)
- الدواء مستحضر يؤثر على صحتك و استهلاكه خلافا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب و طريقة الاستعمال المنصوص عليها و تعليمات الصيدلاني الذي صرفها لك
- إن الطبيب و الصيدلي هما الخبيران بالدواء و بنفعه و ضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الادوية في متناول ايدي الاطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات هذه للمريض من قبل الهيئة العامة للغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RotaTeq oral solution 
Rotavirus vaccine (live)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
One dose (2 ml) contains:

rotavirus type* G1	not less than 2.2 x 106 IU1, 2
rotavirus type* G2	not less than 2.8 x 106 IU1, 2
rotavirus type* G3	not less than 2.2 x 106 IU1, 2
rotavirus type* G4	not less than 2.0 x 106 IU1, 2
rotavirus type* P1A[8]	not less than 2.3 x 106 IU1, 2

* human-bovine rotavirus reassortants (live), produced in Vero cells.

1 Infectious Units
2 As lower confidence limit (p = 0.95)

Excipients with known effect
This vaccine contains 1080 milligrams sucrose and 37.6 milligrams sodium (see section 4.4). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral Solution
Pale yellow clear liquid that may have a pink tint

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1).</p><p>&nbsp;</p><p>RotaTeq is to be used on the basis of official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>&nbsp;</p><p>From birth to 6 weeks</p><p>RotaTeq is not indicated in this subset of paediatric population.</p><p>&nbsp;</p><p>The safety and efficacy of RotaTeq in individuals from birth to 6 weeks of age have not been established.</p><p>&nbsp;</p><p>From 6 weeks to 32 weeks</p><p>The vaccination course consists of three doses.</p><p>The first dose may be administered from the age of 6 weeks and no later than the age of 12 weeks.</p><p>&nbsp;</p><p>RotaTeq may be given to infants who were born prematurely provided that the period of gestation was at least 25 weeks. These infants should receive the first dose of RotaTeq at least six weeks after birth (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>There should be intervals of at least 4 weeks between doses.</p><p>&nbsp;</p><p>It is preferable that the vaccination course of three doses should be completed by the age of</p><p>20-22 weeks. If necessary, the third (last) dose may be given up to the age of 32 weeks (see section 5.1).</p><p>&nbsp;</p><p>As no data exist regarding the interchangeability of RotaTeq with another rotavirus vaccine, it is recommended that infants who receive RotaTeq for the first immunisation against rotavirus should receive this same vaccine for the subsequent doses.</p><p>&nbsp;</p><p>If it is observed or strongly suspected that an incomplete dose has been swallowed (e.g., infant spits or regurgitates the vaccine), a single replacement dose may be given at the same vaccination visit<em>, </em>however, this has not been studied in clinical trials. If the problem recurs, additional replacement doses should not be given.</p><p>&nbsp;</p><p>No further doses are recommended after completion of the 3-dose vaccination course (see sections 4.4 and 5.1 regarding available information on persistence of protection).</p><p>&nbsp;</p><p>From 33 weeks to 18 years</p><p>RotaTeq is not indicated in this subset of paediatric population.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>RotaTeq is for <strong>oral </strong>administration only.</p><p>&nbsp;</p><p>RotaTeq SHOULD UNDER NO CIRCUMSTANCES BE INJECTED.</p><p>&nbsp;</p><p>RotaTeq may be given without regard to food, liquid, or breast milk. See section 6.6 for administration instructions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity after previous administration of rotavirus vaccines.
Previous history of intussusception.

Subjects with congenital malformation of the gastrointestinal tract that could predispose to intussusception.

Infants who have known or suspected immunodeficiency (see sections 4.4 and 4.8).

Administration of RotaTeq should be postponed in infants suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication for immunisation.

The administration of RotaTeq should be postponed in subjects suffering from acute diarrhoea or vomiting.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>As with all vaccines, appropriate medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine (see section 4.8).</p><p>&nbsp;</p><p>No safety or efficacy data are available from clinical trials regarding administration of RotaTeq to immunocompromised infants, those exposed in utero to an immunosuppressive treatment, infants infected with HIV or infants who have received a blood transfusion or immunoglobulins within 42 days of dosing. Asymptomatic HIV infection is not expected to affect the safety or efficacy of</p><p>RotaTeq. However, in the absence of sufficient data, administration of RotaTeq to asymptomatic HIV- infected infants is not recommended. Administration of RotaTeq to infants who have been exposed in utero to an immunosuppressive treatment should be based on careful consideration of potential benefits and risks.</p><p>&nbsp;</p><p>Cases of gastroenteritis associated with vaccine virus have been reported post marketing in infants with severe combined immunodeficiency (SCID, see section 4.3).</p><p>&nbsp;</p><p>In trials, RotaTeq was shed in the stools of 8.9 % of vaccine recipients almost exclusively in the week after dose 1 and in only one vaccine recipient (0.3 %) after dose 3. Peak excretion occurred within</p><p>7 days of dosing. Transmission of vaccine virus strains to non-vaccinated contacts has been observed post-marketing. RotaTeq should be administered with caution to individuals with close contacts who are immunodeficient (e.g., individuals with malignancies or who are otherwise immunocompromised or individuals receiving immunosuppressive therapy). Also, those caring for recent vaccinees should observe careful hygiene especially when handling excreta.</p><p>&nbsp;</p><p>In a clinical study, RotaTeq was administered to approximately 1,000 infants who were born at a gestational age of 25 to 36 weeks. The first dose was administered from 6 weeks after birth. The safety and efficacy of RotaTeq were comparable between this subset of infants and infants born at term.</p><p>However, 19 of the approximately 1,000 infants were born at a gestational age of 25 to 28 weeks, 55 were born at a gestational age of 29 to 31 weeks and the remainder was born at a gestational age of between 32 and 36 weeks. See sections 4.2 and 5.1.</p><p>&nbsp;</p><p>Intussusception</p><p>&nbsp;</p><p>As a precaution, healthcare professionals should follow-up on any symptoms indicative of intussusception (severe abdominal pain, persistent vomiting, bloody stools, abdominal bloating and/or high fever) since data from observational studies indicate an increased risk of intussusception, mostly within 7 days after rotavirus vaccination (see section 4.8). Parents/guardians should be advised to promptly report such symptoms to their healthcare provider.</p><p>&nbsp;</p><p>For subjects with a predisposition for intussusception, see section 4.3.</p><p>&nbsp;</p><p>Safety or efficacy data are not available for infants with active gastrointestinal illnesses (including chronic diarrhoea) or growth retardation. Administration of RotaTeq may be considered with caution in such infants when, in the opinion of the physician, withholding the vaccine entails a greater risk.</p><p>&nbsp;</p><p>The level of protection provided by RotaTeq is based on the completion of all 3 doses. As with any vaccine, vaccination with RotaTeq may not result in complete protection in all recipients. RotaTeq does not protect against gastroenteritis due to other pathogens than rotavirus.</p><p>&nbsp;</p><p>Clinical trials of efficacy against rotavirus gastroenteritis were performed in Europe, the United States, Latin America, and Asia. During these trials, the most common circulating rotavirus genotype was G1P[8], while rotavirus genotypes G2P[4], G3P[8], G4P[8], and G9P[8] were identified less often.</p><p>The extent of protection that RotaTeq might provide against other rotavirus types and in other populations is unknown.</p><p>&nbsp;</p><p>No clinical data are available on the use of RotaTeq for post-exposure prophylaxis.</p><p>&nbsp;</p><p>The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born &le;28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p><p>&nbsp;</p><p>RotaTeq SHOULD UNDER NO CIRCUMSTANCES BE INJECTED.</p><p>&nbsp;</p><p><u>Sucrose</u></p><p>RotaTeq contains sucrose. Patients with rare hereditary problems of fructose intolerance,</p><p>glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine. See section 2.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This vaccine contains 37.6 mg sodium per dose, equivalent to 1.88% of the WHO recommended maximum daily intake of 2 g sodium for an adult. See section 2.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Co-administration of RotaTeq with vaccines containing one or more of the following antigens at approximately 2, 4 and 6 months of age demonstrated that the immune responses and the safety profiles of the administered vaccines were unaffected:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diphtheria-tetanus-acellular pertussis vaccine (DTaP)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Haemophilus</em><em> </em><em>influenzae </em>type b vaccine (Hib)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactivated poliomyelitis vaccine (IPV)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis B vaccine (HBV)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumococcal conjugate vaccine (PCV)</p><p>&nbsp;</p><p>Co-administration of RotaTeq with DTaP-IPV-HBV-Hib vaccine (Infanrix hexa) at approximately 2, 3, and 4 months of age demonstrated that the immune responses and the safety profiles of the</p><p>co-administered vaccines were unaffected compared to separate administrations.</p><p>&nbsp;</p><p>Co-administration of RotaTeq with a group C meningococcal conjugate vaccine (MenCC, the vaccine studied was a tetanus toxoid conjugate) at 3 and 5 months of age (and mostly at the same time as DTaP-IPV-Hib vaccine), followed by a third dose of RotaTeq at approximately 6 months of age, demonstrated that the immune responses to RotaTeq and MenCC were unaffected. Co-administration resulted in an acceptable safety profile.</p><p>&nbsp;</p><p>Concomitant administration of RotaTeq and oral poliomyelitis vaccine (OPV) did not affect the immune response to the poliovirus antigens. Although concomitant administration of OPV slightly reduced the immune response to rotavirus vaccine, there is currently no evidence that clinical protection against severe rotavirus gastroenteritis would be affected. The immune response to RotaTeq was unaffected when OPV was administered two weeks after RotaTeq.</p><p>&nbsp;</p><p>Therefore, RotaTeq can be given concomitantly with monovalent or combination infant vaccines containing one or more of the following antigens: DTaP, Hib, IPV or OPV, HBV, PCV and MenCC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RotaTeq is intended for use in infants only. Thus human data on use during pregnancy or lactation are not available and animal fertility or reproduction studies have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]--></p><p>a.&nbsp; <u>Summary of the safety profile</u></p><p>In a subset of infants from 3 placebo-controlled clinical trials (n=6,130 recipients of RotaTeq and 5,560 placebo recipients), RotaTeq was evaluated for all adverse events within 42 days of vaccination with or without concomitant use of other paediatric vaccines. Overall, 47 % of infants given RotaTeq experienced an adverse reaction compared with 45.8 % of infants given placebo. The most commonly reported adverse reactions that occurred more frequently with vaccine than with placebo were pyrexia (20.9 %), diarrhoea (17.6 %) and vomiting (10.1 %).</p><p>&nbsp;</p><p>Serious adverse reactions were assessed in all participants (36,150 recipients of RotaTeq and</p><p>35,536 placebo recipients) of 3 clinical trials for up to 42 days after each dose. The overall frequency of these serious adverse reactions was 0.1 % among recipients of RotaTeq and 0.2 % among placebo recipients.</p><p>&nbsp;</p><p>b.&nbsp; <u>Tabulated summary of adverse reactions</u></p><p>Adverse reactions more common in the vaccine group in clinical trials are listed below per system organ class and frequency. Based on pooled data from 3 clinical trials in which 6,130 infants received RotaTeq and 5,560 received placebo, the adverse reactions listed occurred with excess incidences in RotaTeq recipients compared to placebo recipients of between 0.2 % and 2.5 %.</p><p>&nbsp;</p><p>Frequencies are reported as:</p><p>Very common (&ge;1/10); Common (&ge;1/100, &lt;1/10); Uncommon (&ge;1/1,000, &lt;1/100); Rare (&ge;1/10,000,</p><p>&lt;1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Adverse reactions following administration of RotaTeq in clinical trials and adverse events reported</p><p>post-marketing (in italics)</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Adverse Reaction/Event</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nasopharyngitis, otitis media</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Anaphylactic</em><em> </em><em>reaction</em><sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p><em>Haematochezia</em><sup>&dagger;</sup>, Abdominal pain upper</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p><em>Intussusception </em><sup>&alpha;</sup> <sup>*</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Urticaria</em><sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Angioedema</em><sup>&Dagger;</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Irritability</em><sup>&Dagger;</sup></p></td></tr></tbody></table><p><sup>&dagger;</sup> This adverse reaction was identified through post-marketing surveillance. The frequency category was estimated based on relevant clinical trials.</p><p><sup>&alpha;</sup> The frequency category was estimated based on observational study data.</p><p>&nbsp;</p><p>*&nbsp; See section 4.4.</p><p><sup>&Dagger;</sup> Post-marketing adverse events (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>c.&nbsp; <u>Description</u><u> </u><u>of</u><u> </u><u>selected adverse reactions</u></p><p>Kawasaki disease was reported in 5 of 36,150 vaccine recipients (&lt;0.1 %) and 1 of 35,536 placebo recipients (&lt;0.1 %) with a relative risk (RR) of 4.9 [95 % CI, 0.6 &ndash; 239.1] (not statistically significant). No increased risk of Kawasaki disease was observed among infants receiving RotaTeq in a large post- marketing observational safety surveillance study (see section 5.1).</p><p>&nbsp;</p><p><u>Intussusception</u></p><p>Data from observational safety studies performed in several countries indicate that rotavirus vaccines carry an increased risk of intussusception, with up to 6 additional cases per 100,000 infants within</p><p>7 days of vaccination. There is limited evidence of a smaller increased risk following the second dose. The background incidence of intussusception in infants less than one year of age in these countries ranged from 25 to 101 per 100,000 infants per year. It remains unclear whether rotavirus vaccines affect the overall incidence of intussusception based on longer periods of follow up (see section 4.4).</p><p>&nbsp;</p><p>d.&nbsp; <u>Other</u><u> </u><u>special</u><u> </u><u>populations</u></p><p>Apnoea in very premature infants (born &le;28 weeks of gestation) (see section 4.4)</p><p>&nbsp;</p><p>Gastroenteritis with vaccine viral shedding in infants with Severe Combined Immunodeficiency Disease (SCID) has been reported post-marketing.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of administration of higher than recommended doses of RotaTeq.</p><p>&nbsp;</p><p>In general, the adverse event profile reported with overdose was comparable to that observed with recommended doses of RotaTeq.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vaccines, Viral Vaccine ATC code: <strong>J07BH02</strong>. <u>Efficacy</u></p><p>In clinical trials, efficacy was demonstrated against gastroenteritis due to rotavirus of genotypes G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8].</p><p>&nbsp;</p><p>The protective efficacy of RotaTeq was evaluated in two ways in the placebo-controlled Rotavirus Efficacy and Safety Trial (REST):</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 5,673 vaccinated infants (2,834 in the vaccine group) protective efficacy was measured as a reduction in the incidence of rotavirus (RV) gastroenteritis caused by vaccine G genotypes (G1-G4) that occurred at least 14 days after the third dose of vaccine through the first full rotavirus season after vaccination.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 68,038 vaccinated infants (34,035 in the vaccine group) protective efficacy was measured as a reduction in the rate of hospitalisations and emergency department visits for RV gastroenteritis from 14 days after the third dose.</p><p>&nbsp;</p><p>The results of these analyses are presented in the following tables.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p>Reduction in incidence of RV gastroenteritis through one full season post-vaccination</p><p>(RotaTeq n=2,834) (% [95 % CI])</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>Efficacy against any severity by rotavirus genotype</p></td></tr><tr><td style="vertical-align:top"><p>Severe*</p><p>disease (G1-G4)</p></td><td style="vertical-align:top"><p>Any</p><p>severity (G1-G4)</p></td><td style="vertical-align:top"><p>G1</p></td><td style="vertical-align:top"><p>G2</p></td><td style="vertical-align:top"><p>G3</p></td><td style="vertical-align:top"><p>G4</p></td><td style="vertical-align:top"><p>G9</p></td></tr><tr><td style="vertical-align:top"><p>98.0 % [88.3, 100.0]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>74.0 % [66.8,</p><p>79.9]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>74.9 % [67.3, 80.9]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>63.4 % [2.6, 88.2]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>82.7 % [&lt;0, 99.6]</p></td><td style="vertical-align:top"><p>48.1 % [&lt;0, 91.6]</p></td><td style="vertical-align:top"><p>65.4 % [&lt;0, 99.3]</p></td></tr></tbody></table><p>*&nbsp; Severe defined as a score &gt;16/24 using a validated clinical scoring system based on the intensity and duration of symptoms (fever, vomiting, diarrhoea and behavioural changes)</p><p><sup>&dagger;</sup> Statistically significant</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Reduction in hospitalisations and emergency department visits for RV gastroenteritis for up to 2 years post-vaccination</p><p>(RotaTeq n=34,035) (% [95 % CI])</p></td></tr><tr><td style="vertical-align:top"><p>G1-G4</p></td><td style="vertical-align:top"><p>G1</p></td><td style="vertical-align:top"><p>G2</p></td><td style="vertical-align:top"><p>G3</p></td><td style="vertical-align:top"><p>G4</p></td><td style="vertical-align:top"><p>G9</p></td></tr><tr><td style="vertical-align:top"><p>94.5 %</p></td><td style="vertical-align:top"><p>95.1 %</p></td><td style="vertical-align:top"><p>87.6 %</p></td><td style="vertical-align:top"><p>93.4 %</p></td><td style="vertical-align:top"><p>89.1 %</p></td><td style="vertical-align:top"><p>100 %</p></td></tr><tr><td style="vertical-align:top"><p>[91.2, 96.6]&dagger;</p></td><td style="vertical-align:top"><p>[91.6, 97.1]&dagger;</p></td><td style="vertical-align:top"><p>[ 0, 98.5]</p></td><td style="vertical-align:top"><p>[49.4, 99.1]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>[52.0, 97.5]<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>[69.6, 100]<sup>&dagger;</sup></p></td></tr></tbody></table><p><sup>&dagger;</sup> Statistically significant</p><p>&nbsp;</p><p>The reduction in incidence of RV gastroenteritis caused by genotypes G1-G4 during the second rotavirus season after vaccination was 88.0 % [95 % CI 49.4, 98.7] for severe disease and 62.6 % [95 % CI 44.3, 75.4] for disease of any severity.</p><p>&nbsp;</p><p>Efficacy against genotypes G2P[4], G3P[8], G4P[8] and G9P[8] rotavirus was based on fewer cases than for G1. The efficacy observed against G2P[4] most likely resulted from the G2 component of the vaccine.</p><p>&nbsp;</p><p>In a combined post-hoc analysis of REST and another phase III study, the vaccine efficacy against G1-, G2-, G3- and G4-serotype RVG cases (any severity) was 61.5 % [95 % CI: 14.2; 84.2] among infants who were &gt;26 to &le;32 weeks of age at dose 3.</p><p>&nbsp;</p><p>There was an extension of REST conducted in Finland only. This Finnish Extension Study (FES) included a subset of 20,736 subjects that had been enrolled previously in REST. The infants were followed for up to 3 years post-vaccination in the FES.</p><p>&nbsp;</p><p>In REST there were 403 healthcare encounters (20 in the vaccine group and 383 in the placebo group) associated with G1-G4 and G9 RV gastroenteritis in the per protocol population. The additional data from the FES increased the number by 136 encounters in total, including 9 in the vaccine group and 127 in the placebo group. Overall, 31 % and 25 % of the encounters in the respective groups occurred during the FES.</p><p>&nbsp;</p><p>Based upon combined data from REST and the FES, the reduction up to 3 years post-vaccination in the rate of hospitalisations and emergency department visits for RV gastroenteritis was 94.4 %</p><p>(95 % CI: 91.6, 96.2) for genotypes G1-G4<strong>, </strong>95.5 % (95 % CI: 92.8, 97.2) for genotype G1, 81.9 %</p><p>(95 % CI: 16.1, 98.0) for genotype G2, 89.0 % (95 % CI: 53.3, 98.7) for genotype G3, 83.4 %</p><p>(95 % CI: 51.2, 95.8) for genotype G4, and 94.2 % (95 % CI: 62.2, 99.9) for genotype G9. During year 3, there were no health care contacts for RV gastroenteritis in the vaccine group (n=3,112) and one (non-typeable) in the placebo group (n=3,126).</p><p>&nbsp;</p><p>A complete 3-dose vaccination series of RotaTeq should be administered (see section 4.2) to provide the level and duration of protection against rotavirus gastroenteritis that was observed in the clinical studies. However, post hoc analyses indicated that RotaTeq achieved some reduction in the numbers of cases of rotavirus gastroenteritis of sufficient severity to require hospitalisation or an emergency department visit before completion of all three doses (i.e. from approximately 14 days after administration of the first dose onwards).</p><p>&nbsp;</p><p><u>Efficacy in premature infants</u></p><p>In REST, RotaTeq was administered to approximately 1,000 infants who were born at a gestational age of 25 to 36 weeks. The efficacy of RotaTeq was comparable between this subset of infants and infants born at term.</p><p>&nbsp;</p><p><u>Post-marketing observational safety surveillance study</u></p><p>In a large prospective post-marketing observational study in the US, the risk of Kawasaki disease was analysed among 85,150 infants receiving one or more doses of RotaTeq (17,433 person-years of follow-up).</p><p>&nbsp;</p><p>During the 0-30 day follow-up period after vaccination, there were no statistically significant difference in the rate of Kawasaki disease compared with the expected background rate. In addition, there was no statistically significant increased risk of this adverse event during the 0-30 day follow-up period compared with a concurrent control group of infants who received DTaP, but not RotaTeq (n=62,617, 12,339 person-years of follow-up). One chart-confirmed case was recorded among infants vaccinated with RotaTeq compared with one chart-confirmed case among concurrent DTaP controls (relative risk = 0.7, 95 % CI: 0.01-55.56). In the general safety analyses, no specific safety concerns were identified.</p><p>&nbsp;</p><p><u>Effectiveness study data</u></p><p>Post marketing studies demonstrating effectiveness to prevent RV gastroenteritis (RVGE)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Study design</p><p>(Region)</p></td><td style="vertical-align:top"><p>Study population</p></td><td style="vertical-align:top"><p>Endpoints</p></td><td style="vertical-align:top"><p>Effectiveness</p><p>% [95%CI]</p></td><td style="vertical-align:top"><p>RV seasons</p></td></tr><tr><td style="vertical-align:top"><p>Claims database analysis (US)</p></td><td style="vertical-align:top"><p>33,140 vaccinated</p><p>26,167 unvaccinated Aged &ge;7 months Received 3 doses</p></td><td style="vertical-align:top"><p>Hospitalization and Emergency Department (ED) visits due to RVGE</p><p>&nbsp;</p><p>Outpatients due to RVGE</p><p>&nbsp;</p><p>Hospitalization and ED visits due to all cause gastroenteritis</p></td><td style="vertical-align:top"><p>100% [87,100]</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>96% [76,100]</p><p>&nbsp;</p><p>&nbsp;</p><p>59% [47,68]</p></td><td style="vertical-align:top"><p>2007-2008</p></td></tr><tr><td style="vertical-align:top"><p>Cohort study (France)</p></td><td style="vertical-align:top"><p>1,895 vaccinated with 3 doses</p><p>2,102 unvaccinated</p><p>Aged &lt;2 years</p></td><td style="vertical-align:top"><p>Hospitalization due to RVGE</p></td><td style="vertical-align:top"><p>98% [83,100]</p></td><td style="vertical-align:top"><p>2007-2008</p><p>2008-2009</p></td></tr><tr><td style="vertical-align:top"><p>Case-control</p></td><td style="vertical-align:top"><p>402 cases</p></td><td rowspan="13" style="vertical-align:top"><p>Hospitalization and ED visits due to RVGE</p><p><strong><em>Strain-specific</em></strong></p><p>- G1P[8]</p><p>- G2P[4]</p><p>- G3P[8]</p><p>- G12P[8]</p><p><strong><em>Age-specific</em></strong></p><p>-&nbsp; 1st year of life</p><p>-&nbsp; 2nd year of life</p><p>-&nbsp; 3rd year of life</p><p>-&nbsp; 4th year of life</p><p>-&nbsp; 5th year of life</p><p>-&nbsp; 6th-7th year of life</p></td><td style="vertical-align:top"><p>80% [74,84]</p></td><td style="vertical-align:top"><p>2011-2012</p></td></tr><tr><td style="vertical-align:top"><p>study (US)</p></td><td style="vertical-align:top"><p>2,559 controls*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2012-2013</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aged &lt;8 years</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Received 3 doses</p></td><td style="vertical-align:top"><p>89% [55,97]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>87% [65,95]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>80% [64,89]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>78% [71,84]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>91% [78,96]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>82% [69,89]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>88% [78,93]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>76% [51,88]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>60% [16,81]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>69% [43,84]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*RV-negative acute gastroenteritis controls</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>The immunological mechanism by which RotaTeq protects against rotavirus gastroenteritis is not completely understood. No immunological correlate of protection has currently been identified for rotavirus vaccines. In phase III studies between 92.5 % and 100 % of recipients of RotaTeq achieved a significant rise in serum anti-rotavirus IgA after a three-dose regimen. The vaccine induces an immune response (i.e., appearance of serum neutralising antibody) to the five human-rotavirus proteins expressed on the reassortants (G1, G2, G3, G4 and P[8]).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A single and repeated dose oral toxicity study in mice suggests no special hazard to humans. The dose administered to mice was approximately 2.79 x 10<sup>8</sup> infectious units per kg (about 14-fold the projected infant dose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Sodium citrate</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Sodium hydroxide</p><p>Polysorbate 80</p><p>Culture media (containing inorganic salts, amino acids and vitamins) Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
2 years

RotaTeq should be administered promptly after removal from refrigeration.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2 &deg;C to 8 &deg;C).</p><p>&nbsp;</p><p>Keep the dosing tube in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 ml solution in a pre-filled squeezable tube (LDPE), with a twist-off cap (HDPE) in a protective bag, pack size of 1 or 10 pre-filled squeezable tube(s).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The vaccine is to be administered orally without mixing with any other vaccines or solutions. Do not dilute</p><p><img alt="" width="486" height="528" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme B.V., 
Waarderweg 39 ,2031 BN Haarlem, 
P.O.Box 581, 2003 Haarlem, 
The Netherlands


Manufacturer: 
Merck, Sharp & Dohme LLC, 770 Sumneytown Pike, P.O. Box
4, West Point, PA 19486, US.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>